


# GRIDD is the first global, patient-driven research project on the impact of dermatological diseases

Nirohshah Trialonis-Suthakharan, Rachael Pattinson, Christine Janus, Jennifer Austin, Chris Bundy, Matthias Augustin



Adds **new knowledge** to existing information about the impact of living with a dermatological condition.

PRIDD, developed using both **qualitative and quantitative methods**, will produce much needed patient impact data.

It will **raise global awareness, locally, regionally and internationally**, across conditions.

This information will influence **better decision-making and resource allocation for clinicians and policy makers** and ultimately benefit patients.

## Introduction

Existing patient-reported outcome measures (PROMs) and metrics (e.g. DALYs) in dermatology arguably underestimate the true impact of dermatological conditions on patients' lives. This impacts on treatment decision-making and resources allocation. To fully understand the impact of dermatological conditions, information must be obtained largely from patients.


**GRIDD is a project of:**



## Objective

GRIDD will develop a new comprehensive Patient-Reported Impact of Dermatological Diseases (PRIDD) measure.

## Methodology




## Results

**Phase 1** Systematic review, using the COSMIN methodology, showed no existing gold standard measure of impact.



**Phase 2** Concept elicitation study of 68 people from 29 countries representing 29 dermatological conditions.

Data resulted in the first conceptual framework of the impact of dermatological conditions with five domains:



Impact items were generated based on the conceptual framework. These items formed the basis of the Delphi.

**Phase 3** Delphi study of 1154 from 61 countries and 90 dermatological conditions. Patients prioritised which of the 263 potential impact items should be included in PRIDD. The results generated the first draft of PRIDD, consisting of 33 items across five domains, ready for pilot-testing in the next stage of development.

**Phase 4** Cognitive interviews will be conducted with approx. 30 patients to evaluate PRIDD's comprehensiveness, comprehensibility and relevance (content validity).

## Cardiff University

Rachael Pattinson, PhD Candidate  
School of Healthcare Sciences  
College of Biomedical and Life Sciences

E-mail: PattinsonR@cardiff.ac.uk



University Medical Center  
Hamburg-Eppendorf

For more information, please visit the website:

<https://globalskin.org/research>

